Literature DB >> 28116482

Is Unilateral Neck Surgery Feasible in Patients with Sporadic Primary Hyperparathyroidism and Double Negative Localisation?

D M Scott-Coombes1, J Rees2, G Jones3, M J Stechman4.   

Abstract

INTRODUCTION: Ultrasound and Tc99mMIBI scans are used to localise parathyroid tumours in sporadic primary hyperparathyroidism (pHPT). Intra-operative PTH (ioPTH) assay facilitates unilateral neck exploration (UNE). When both ultrasound and MIBI are negative, it is our policy to explore the left side of the neck and only proceed to bilateral neck exploration (BNE) when either a tumour is not found or when ioPTH does not fall to >50% of the highest pre-excision value. The aim of this study was to investigate the outcome of our approach to 'double negative' patients.
METHODS: A retrospective analysis of patients undergoing primary parathyroidectomy for pHPT. Data were obtained from a prospective surgical database and the hospital electronic patient record.
RESULTS: Between January 2004 and November 2014, 746 patients underwent a parathyroidectomy for pHPT. Those who did not have both pre-operative scans, ioPTH or a minimum of 6-month follow-up were excluded. Of 552 patients, 111 (20%) had double negative scans (group A), and in 441, either one or both scans were positive (group B). Median age was 61.5 years (range 10-88). Pre-operative PTH level was significantly lower in group A: 11.8 pmol/l (range 3.1-38.8) versus 14.9 pmol/l (range 2.8-101.6; P < 0.01). Median tumour weight was significantly lower in group A: 280 mg (range 50-3710) versus 573 mg (range 10-12,000; P < 0.01). Overall rate of multiple gland disease (MGD) was 11%; 24% in group A and 7% in group B (P < 0.01). Overall rate of UNE in Group A was 28% and converse to the rate in Group B (76%; P < 0.01). Sensitivity and specificity of ioPTH to detect MGD were 98 and 98% in Group A versus 98 and 100% in Group B. First-time cure rate was 92.7% in group A and 96.8% in group B (P < 0.05).
CONCLUSION: A double negative scan is associated with small tumours and higher rates of MGD. Despite these challenges, surgery is successful in this group of patients reinforcing the message that negative localisation is not a contraindication for parathyroidectomy. We demonstrated that it is feasible to offer unilateral neck surgery to 28% of patients with double negative scans. A randomised trial is needed to compare BNE with ioPTH/UNE in this select population.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28116482     DOI: 10.1007/s00268-017-3891-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  26 in total

1.  Primary hyperparathyroidism and negative Tc99 sestamibi imaging: to operate or not?

Authors:  Benzon M Dy; Melanie L Richards; Bianca J Vazquez; Geoffrey B Thompson; David R Farley; Clive S Grant
Journal:  Ann Surg Oncol       Date:  2012-03-22       Impact factor: 5.344

2.  Primary hyperparathyroidism: an analysis of failure of parathyroidectomy.

Authors:  A Bagul; H P Patel; D Chadwick; B J Harrison; S P Balasubramanian
Journal:  World J Surg       Date:  2014-03       Impact factor: 3.352

3.  The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism.

Authors:  Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty
Journal:  JAMA Surg       Date:  2016-10-01       Impact factor: 14.766

4.  Results of surgery for sporadic primary hyperparathyroidism in patients with preoperatively negative sestamibi scintigraphy and ultrasound.

Authors:  Anders O J Bergenfelz; Göran Wallin; Svante Jansson; Håkan Eriksson; Hans Mårtensson; Peer Christiansen; Eva Reihnér
Journal:  Langenbecks Arch Surg       Date:  2011-01       Impact factor: 3.445

Review 5.  Intraoperative adjuncts in surgery for primary hyperparathyroidism.

Authors:  Barney J Harrison; Frederic Triponez
Journal:  Langenbecks Arch Surg       Date:  2009-07-10       Impact factor: 3.445

6.  Negative preoperative localization studies are highly predictive of multiglandular disease in sporadic primary hyperparathyroidism.

Authors:  Frederic Sebag; Johnathan G H Hubbard; Sylvie Maweja; Claudia Misso; Laurent Tardivet; Jean-Francois Henry
Journal:  Surgery       Date:  2003-12       Impact factor: 3.982

Review 7.  Minimally invasive parathyroidectomy: benefits and requirements of localization, diagnosis, and intraoperative PTH monitoring. long-term results.

Authors:  Douglas L Fraker; Hasly Harsono; Robert Lewis
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

8.  Surgery for hyperparathyroidism in image-negative patients.

Authors:  Rodney K Chan; Daniel T Ruan; Atul A Gawande; Francis D Moore
Journal:  Arch Surg       Date:  2008-04

9.  Surgery for patients with primary hyperparathyroidism and negative sestamibi scintigraphy--a feasibility study.

Authors:  Mark Thier; Erik Nordenström; Anders Bergenfelz; Johan Westerdahl
Journal:  Langenbecks Arch Surg       Date:  2009-06-23       Impact factor: 3.445

Review 10.  Surgical strategy for sporadic primary hyperparathyroidism an evidence-based approach to surgical strategy, patient selection, surgical access, and reoperations.

Authors:  Radu Mihai; Marcin Barczynski; Maurizio Iacobone; Antonio Sitges-Serra
Journal:  Langenbecks Arch Surg       Date:  2009-06-25       Impact factor: 3.445

View more
  2 in total

1.  Intraoperative Parathyroid Hormone Assay Remains Predictive of Cure in Renal Impairment in Patients with Single Parathyroid Adenomas.

Authors:  R J Egan; H Iliff; M J Stechman; D M Scott-Coombes
Journal:  World J Surg       Date:  2018-09       Impact factor: 3.352

2.  Primary hyperparathyroidism: findings from the retrospective evaluation of cases over a 6-year period from a regional UK centre.

Authors:  Joseph M Pappachan; Mohamed Nabil Elnaggar; Ravinder Sodi; Kahtan Jbeili; Paul R Smith; Ian M Lahart
Journal:  Endocrine       Date:  2018-07-17       Impact factor: 3.633

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.